Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Primary objective:
- Compare disease-free survival in women with human epidermal growth factor receptor 2
(HER2)-neu-expressing node-positive or high-risk node-negative operable breast cancer
treated with adjuvant doxorubicin, cyclophosphamide, and docetaxel with or without
trastuzumab (Herceptin) vs trastuzumab, docetaxel, and carboplatin.
Secondary objective:
- Compare overall survival of participants treated with these regimens.
- Compare the toxic effects (including cardiac) of these regimens in these participants.
- Compare quality of life of participants treated with these regimens.
- Compare pathologic and molecular markers for predicting efficacy of these regimens in
these participants.
- For substudy: Compare peripheral levels of shed HER2-neu extracellular domain with
fluorescence in situ hybridization in predicting outcome in participants treated with
these regimens.